Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy

Xin Wu1,*, Baoyue Ding1,2,*, Jing Gao3,*, Huanyun Wang4, Wei Fan1, Xiang Wang1,5, Wei Zhang1, Xiaoyu Wang1, Lihua Ye1, Min Zhang1, Xueying Ding3, Jiyong Liu1, Quangang Zhu1, Shen Gao11Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai; 2Medical College of Ji...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhu Q, Liu J, Ding X, Zhang M, Ye L, Wang X, Zhang W, Fan W, Wang H, Gao J, Ding B, Wu X, Gao S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9594f56739a64e37a14af350f73b043d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9594f56739a64e37a14af350f73b043d
record_format	dspace
spelling	oai:doaj.org-article:9594f56739a64e37a14af350f73b043d2021-12-02T02:42:08ZSecond-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy1176-91141178-2013https://doaj.org/article/9594f56739a64e37a14af350f73b043d2011-08-01T00:00:00Zhttp://www.dovepress.com/second-generation-aptamer-conjugated-psma-targeted-delivery-system-for-a8111https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Xin Wu1,, Baoyue Ding1,2,, Jing Gao3,, Huanyun Wang4, Wei Fan1, Xiang Wang1,5, Wei Zhang1, Xiaoyu Wang1, Lihua Ye1, Min Zhang1, Xueying Ding3, Jiyong Liu1, Quangang Zhu1, Shen Gao11Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai; 2Medical College of Jiaxing University, Jiaxing; 3School of Pharmacy, Second Military Medical University, Shanghai; 4School of Pharmacy, Inner Mongolia Medical College, Hohhot; 5No. 98 Hospital of PLA, Huzhou, People&rsquo;s Republic of China These authors contributed equally to this workBackground: miR-15a and miR-16-1 have been identified as tumor suppressor genes in prostate cancer, but their safe and effective delivery to target cells is key to the successful use of this therapeutic strategy. RNA aptamer A10 has been used as a ligand, targeting prostate cancer cells that express prostate-specific membrane antigen (PSMA). Compared with A10, the binding of the second-generation RNA aptamer, A10-3.2, to PSMA is more efficient.Methods: A10-3.2 was investigated as a PSMA-targeting ligand in the design of a polyamidoamine (PAMAM)-based microRNA (miR-15a and miR-16-1) vector to prostate cancer cells. Using polyethyleneglycol (PEG) as a spacer, PAMAM was conjugated to aptamer (PAMAM-PEG-APT) and used as a vehicle for miRNA target delivery.Results: Luciferase assays of pGL-3 expression against PC3 (PSMA&minus;) and LNCaP (PSMA+) cells demonstrated that the transfection efficiency of the synthesized DNA/PAMAM-PEG-APT complex was higher than that of the DNA/PAMAM-PEG complex. In addition, cell viability assays of LNCaP (PSMA+) cells showed that, with a N/P ratio of 15:1, the IC50 value of miRNA/PAMAM-PEG-APT was approximately 4.7-fold lower than that of miRNA/PAMAM-PEG.Conclusion: This PSMA-targeted system may prove useful in widening the therapeutic window and allow for selective killing of prostate cancer cells.Keywords: miRNA, aptamer, polyamidoamine, prostate-specific membrane antigen, targeted delivery, prostate cancerZhu QLiu JDing XZhang MYe LWang XZhang WWang XFan WWang HGao JDing BWu XGao SDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2011, Iss default, Pp 1747-1756 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Zhu Q Liu J Ding X Zhang M Ye L Wang X Zhang W Wang X Fan W Wang H Gao J Ding B Wu X Gao S Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
description	Xin Wu1,, Baoyue Ding1,2,, Jing Gao3,, Huanyun Wang4, Wei Fan1, Xiang Wang1,5, Wei Zhang1, Xiaoyu Wang1, Lihua Ye1, Min Zhang1, Xueying Ding3, Jiyong Liu1, Quangang Zhu1, Shen Gao11Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai; 2Medical College of Jiaxing University, Jiaxing; 3School of Pharmacy, Second Military Medical University, Shanghai; 4School of Pharmacy, Inner Mongolia Medical College, Hohhot; 5No. 98 Hospital of PLA, Huzhou, People&rsquo;s Republic of China These authors contributed equally to this workBackground: miR-15a and miR-16-1 have been identified as tumor suppressor genes in prostate cancer, but their safe and effective delivery to target cells is key to the successful use of this therapeutic strategy. RNA aptamer A10 has been used as a ligand, targeting prostate cancer cells that express prostate-specific membrane antigen (PSMA). Compared with A10, the binding of the second-generation RNA aptamer, A10-3.2, to PSMA is more efficient.Methods: A10-3.2 was investigated as a PSMA-targeting ligand in the design of a polyamidoamine (PAMAM)-based microRNA (miR-15a and miR-16-1) vector to prostate cancer cells. Using polyethyleneglycol (PEG) as a spacer, PAMAM was conjugated to aptamer (PAMAM-PEG-APT) and used as a vehicle for miRNA target delivery.Results: Luciferase assays of pGL-3 expression against PC3 (PSMA&minus;) and LNCaP (PSMA+) cells demonstrated that the transfection efficiency of the synthesized DNA/PAMAM-PEG-APT complex was higher than that of the DNA/PAMAM-PEG complex. In addition, cell viability assays of LNCaP (PSMA+) cells showed that, with a N/P ratio of 15:1, the IC50 value of miRNA/PAMAM-PEG-APT was approximately 4.7-fold lower than that of miRNA/PAMAM-PEG.Conclusion: This PSMA-targeted system may prove useful in widening the therapeutic window and allow for selective killing of prostate cancer cells.Keywords: miRNA, aptamer, polyamidoamine, prostate-specific membrane antigen, targeted delivery, prostate cancer
format	article
author	Zhu Q Liu J Ding X Zhang M Ye L Wang X Zhang W Wang X Fan W Wang H Gao J Ding B Wu X Gao S
author_facet	Zhu Q Liu J Ding X Zhang M Ye L Wang X Zhang W Wang X Fan W Wang H Gao J Ding B Wu X Gao S
author_sort	Zhu Q
title	Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
title_short	Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
title_full	Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
title_fullStr	Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
title_full_unstemmed	Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
title_sort	second-generation aptamer-conjugated psma-targeted delivery system for prostate cancer therapy
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/9594f56739a64e37a14af350f73b043d
work_keys_str_mv	AT zhuq secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT liuj secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT dingx secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT zhangm secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT yel secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT wangx secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT zhangw secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT wangx secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT fanw secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT wangh secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT gaoj secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT dingb secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT wux secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy AT gaos secondgenerationaptamerconjugatedpsmatargeteddeliverysystemforprostatecancertherapy
_version_	1718402235835088896

Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy

Ejemplares similares